Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11)
doi.org/10.1200/JCO-26-00769
2nd Annual @RRS_RadRes-@sitcancer Joint Session drew a standing room crowd! Spoke on "Immunological Modulation by Radiation" w/ @everettmoding on the dual, context-dependent role of inflammatory TME in sarcoma vs TNBC/prostate. Thx to @DemariaLab_WCM & @HenningWillers for invite.
Several years ago, Rob Preece, a long-time marathon runner, developed a soreness in his leg that wasn’t going away. Eventually, a lump appeared in the same spot. A biopsy revealed something he never could have expected: a rare and aggressive form of sarcoma called UPS.
Rob’s doctor, @AngelaHong of @Sydney_Uni, told him about a clinical trial supported by #StandUpToCancer and led by @DrDavidKirsch and @EverettModing that was testing a new treatment approach for UPS. Rob enrolled in the trial and now, more than 2 years later, he is cancer-free and enjoying life, including frequent outings with his granddaughter to get ice cream. “This trial was life saving for me.” ❤️
The results of this SU2C-funded clinical trial represented the first significant improvement in the treatment of this form of sarcoma in decades. Learn more about Rob’s story and this cancer research breakthrough at SU2C.link/SarcomaBreakthroug….
Grateful for 2nd Joint @sitcancer & @RRS_RadRes Symposium at #RadRes2026 on radiation/immunology topics, how radiation shapes the anti-tunor response☢️
Inspiring correlative science talks from @everettmoding & @AnthonyNguyenMD + 3 oral abstract talks🙏🙏🙏
Looking forward to more collaborations between our Societies 👍
Despite the Nor'Easter crashing #ASTRO26's party, it's a pleasure to make it to the comprehensive #RadOnc annual meeting for the 3rd year in a row, and present my work in the Moding Lab!
P.S. I hope the organizing team considers #SanDiego for upcoming meetings ☀️😅
Now out in #JCO 👇
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Co-authored by @everettmoding.
Read the article: bit.ly/4xGXj9C
Please join us in congratulating @everettmoding, MD, PhD, for receiving the @RRS_RadRes Scholar-in-Training Excellence in Mentorship award! This award honors an individual who has provided exceptional mentoring to a Scholar-in-Training member. Congratulations!
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Co-authored by @everettmoding.
Read the full article. bit.ly/4xJCsDf
Thank you to @SARCtrials for sponsoring and conducting this trial at 20 sites around the world. This work was supported by a @SU2C Catalyst Grant with support from @Merck, @theNCI, and the DoD. Finally, we are grateful to patients and their caregivers for participating. (11/11)
We are excited about the potential for personalized ctDNA analysis to guide treatment decisions in STS! This work was led by co-first authors Ajay Subramanian, Serey Nouth, and Neda Nemat-Gorgani. (9/11)
Because our panels track all clonal and subclonal tumor mutations, we could follow individual tumor clones noninvasively. We were interested to find that patients with multiple clones detected after surgery had worse outcomes even when their ctDNA levels were similar. (8/11)
Detection of ctDNA MRD at 3 months post-surgery was strongly associated with both disease-free and overall survival, raising the possibility that ctDNA analysis can identify patients who may benefit from additional systemic therapy after radiation and surgery. (7/11)
Patients treated with pembrolizumab, who had significantly better disease-free survival in SU2C-SARC032, had a greater decrease in their ctDNA levels after neoadjuvant therapy, suggesting that ctDNA dynamics could provide an early readout of treatment efficacy. (6/11)
ctDNA levels pre-treatment were strongly associated with disease-free and overall survival, even after adjusting for established clinical risk factors. (5/11)